AR067850A1 - Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit - Google Patents

Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit

Info

Publication number
AR067850A1
AR067850A1 ARP080102569A ARP080102569A AR067850A1 AR 067850 A1 AR067850 A1 AR 067850A1 AR P080102569 A ARP080102569 A AR P080102569A AR P080102569 A ARP080102569 A AR P080102569A AR 067850 A1 AR067850 A1 AR 067850A1
Authority
AR
Argentina
Prior art keywords
group
substituted
pyridyl
alkyl
unsubstituted
Prior art date
Application number
ARP080102569A
Other languages
English (en)
Inventor
Mary Ann Walter
Scott R Gilbertson
Maria Estrella-Jimenez
Jian Gao
Johnny W Peterson
Catherine H Schein
Deliang Chen
Original Assignee
Mission Pharma Co
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mission Pharma Co, Univ Texas filed Critical Mission Pharma Co
Publication of AR067850A1 publication Critical patent/AR067850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen un método para tratar y/o prevenir la pérdida de fluido intestinal en un sujeto que comprende administrarle al sujeto una composicion que comprende una cantidad eficaz para el uso terapéutico de un compuesto o una sal de éste aceptable para el uso farmacéutico, donde la formula general del compuesto se selecciona del grupo que consiste en el grupo de formulas (1) a (9) y cualquier combinacion de éstas, donde 1) R es una estructura de anillo cíclico o bicíclico; 2) R1 es un hidrogeno, una estructura de anillo cíclico o bicíclico; 3) R2 es un hidrogeno, alquilo, una estructura de anillo cíclico o bicíclico; 4) R3 es un hidrogeno, o alquilo; 5) R5 es un hidrogeno, alquilo, una estructura de anillo cíclico o bicíclico; 6) X es un alquilo, oxígeno, un éster, una amina o una amida, 7) Z se selecciona del grupo que consiste en hidrogeno, alquenilo, alquinilo, fenilo, bencilo, halo, fluoro, cloro, bromo, iodo, hidroxilo, ceto, oxo, aldo. carbonato, carboxilo, alcoxilo, éster, carboxamido, amino, amonio, imino, imido, azido, azo, cianato, isociano, isocianato, isotiocianato, nitroxilo, ciano, nitrosooxilo, nitro, nitroso, 4-piridilo, 3-piridilo, 2-piridilo, tioéter, sulfanilo, sulfo, sulfinilo, mercapto, sulfanilo, sulfhidrilo, sulfonamino, tiocianato, alquil amino, ácido hidroxiámico, metilo, etilo, 1,3-dioxilanilo, propilo, iso-propilo, butilo, ter-butilo, alquilo no sustituido o sustituido, ramificado o no ramificado, alquenilo C1-3, arilo no sustituido o sustituido, ramificado o no ramificado, alquilarilo no sustituido o sustituido, ramificado o no ramificado, hidrato de carbono no sustituido a sustituido, ramificado o no ramificado; 8) W se selecciona de! grupo que consiste en CO, NH, metileno, un átomo de azufre, un átomo de oxigeno y tionilo; y 9) n es 0, 1,o más de 1. También se describen composiciones que comprenden compuestos de formula 1 y 4 y un kit o conjunto de elementos para el tratamiento de la pérdida de fluido intestinal en un sujeto, que comprende una cantidad terapéuticamente efectiva de un compuesto a una sal farmacéuticamente aceptable del mismo de formula general seleccionada del grupo que consiste de las formulas 1 a 9. Reivindicacion 2: El método de la reivindicacion 1, donde R está sustituido o no sustituido, y se selecciona del grupo que consiste en fenilo, piranonilo, piridilo, imidazolilo, 1,8-naftiridinilo y N-oxido de piridilo. Reivindicacion 4: El método de la reivindicacion 1, donde R1 esté sustituido o no sustituido, y se selecciona del grupo que consiste en fenilo, piridilo y furanilo. Reivindicacion 14: El método de la reivindicacion 1, donde la composicion se administra en combinacion con una o más drogas adicionales. Reivindicacion 15: El método de la reivindicacion 1, donde la composicion comprende además un antibiotico o un antiinflamatorio. Reivindicacion 78: El conjunto de elementos de la reivindicacion 70, que comprende además una droga seleccionada del grupo que consiste en un antibiotico, un antidiarreico y una droga inhibidora de LT.
ARP080102569A 2007-06-15 2008-06-17 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit AR067850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94437507P 2007-06-15 2007-06-15
US3526908P 2008-03-10 2008-03-10

Publications (1)

Publication Number Publication Date
AR067850A1 true AR067850A1 (es) 2009-10-28

Family

ID=40468705

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102569A AR067850A1 (es) 2007-06-15 2008-06-17 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit

Country Status (12)

Country Link
US (2) US8003692B2 (es)
EP (1) EP2166841A4 (es)
CN (1) CN101784274A (es)
AR (1) AR067850A1 (es)
AU (1) AU2008302667B2 (es)
BR (1) BRPI0813176A2 (es)
CA (1) CA2692004C (es)
CL (1) CL2008001782A1 (es)
CO (1) CO6270184A2 (es)
DO (1) DOP2009000272A (es)
MX (1) MX2009013676A (es)
WO (1) WO2009038842A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
WO2008088771A2 (en) * 2007-01-12 2008-07-24 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
EP2166841A4 (en) * 2007-06-15 2014-05-07 Mission Pharma Co METHODS AND COMPOSITIONS FOR INHIBITING DOME FACTOR AND ADENYLYLCYCLASE
EP2326953B1 (en) * 2008-07-22 2018-03-21 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
KR101762574B1 (ko) * 2009-03-31 2017-07-28 가부시키가이샤 레나사이언스 플라즈미노겐 액티베이터 인히비터-1 저해제
AU2013207510A1 (en) * 2012-01-06 2014-07-31 The Regents Of The University Of California Compositions, methods of use, and methods of treatment
US10092537B2 (en) 2013-04-15 2018-10-09 Renascience Co., Ltd. Use for PAI-1 inhibitor
US9677117B2 (en) 2014-10-08 2017-06-13 Promega Corporation Bioluminescent succinate detection assay
CN105218343B (zh) * 2015-10-26 2017-03-22 乐普药业股份有限公司 一种3‑溴环己‑2‑烯‑1‑酮的合成方法
US10556853B2 (en) * 2017-01-10 2020-02-11 Owen-Barry Pharmaceuticals Inc. Anticonvulsant compounds
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
FI3697785T3 (fi) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066834A (en) * 1974-01-24 1978-01-03 Miles Laboratories, Inc. Cycloalkenyl analogues of prostaglandins E
US4222944A (en) * 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
KR20000068415A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
CA2366877A1 (en) * 1999-03-22 2000-09-28 Stanley Michael Roberts Chemical compounds and their uses
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
AU2002239277A1 (en) * 2000-11-20 2002-05-27 Cor Therapeutics, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
CA2457468A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
EP1456214A2 (en) * 2001-12-14 2004-09-15 Charterhouse Therapeutics Limited Improvements in pharmaceutical compositions
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20030224403A1 (en) * 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
EP1479666A4 (en) * 2002-02-28 2010-10-13 Japan Tobacco Inc ESTER CONNECTION AND THEIR MEDICAL USE
KR20050065624A (ko) * 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
CA2528626A1 (en) * 2003-07-09 2005-01-20 Biolipox Ab Indoles useful in the treatment of inflammation
US7223759B2 (en) * 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
LT2489659T (lt) * 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Atp rišančios kasetės transporterių moduliatoriai
US20080096848A1 (en) * 2004-09-29 2008-04-24 Cytovia Inc. Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007135120A1 (en) * 2006-05-23 2007-11-29 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
EP2166841A4 (en) * 2007-06-15 2014-05-07 Mission Pharma Co METHODS AND COMPOSITIONS FOR INHIBITING DOME FACTOR AND ADENYLYLCYCLASE

Also Published As

Publication number Publication date
MX2009013676A (es) 2010-06-01
CA2692004C (en) 2013-04-09
CN101784274A (zh) 2010-07-21
EP2166841A4 (en) 2014-05-07
AU2008302667A1 (en) 2009-03-26
WO2009038842A3 (en) 2009-12-30
US20120010233A1 (en) 2012-01-12
US8003692B2 (en) 2011-08-23
WO2009038842A2 (en) 2009-03-26
EP2166841A2 (en) 2010-03-31
CA2692004A1 (en) 2009-03-26
CL2008001782A1 (es) 2008-11-03
US20090093519A1 (en) 2009-04-09
AU2008302667B2 (en) 2014-07-10
BRPI0813176A2 (pt) 2014-12-30
CO6270184A2 (es) 2011-04-20
DOP2009000272A (es) 2010-02-15

Similar Documents

Publication Publication Date Title
AR067850A1 (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit
ES2345044T3 (es) 2-piperazin-piridinas utiles para tratar el dolor.
RU2017138972A (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20060972L (no) Pyridylderivater og deres anvendelse som terapeutiske midler
CA2412968A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
AU2017298142B2 (en) Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
RU2011108563A (ru) Способы лечения талассемии
ES2317052T3 (es) Agentes terapeuticos utiles para el tratamiento del dolor.
KR910014350A (ko) 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물
HRP20030450B1 (en) Isoindolin-1-one glucokinase activators
AR024732A1 (es) Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek.
GB1114069A (en) Benzimidazole derivatives and anthelmintic compositions containing them
WO2019204354A1 (en) Spirocyclic compounds
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
PE20090641A1 (es) Amidas heterociclicas
AR036597A1 (es) Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1
RU2011116227A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
ES2141347T3 (es) Amidino-derivados utiles como inhibidores de oxido nitrico sintasa.
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
PT1487829E (pt) Derivados de tiadiazolilpiperazina úteis para o tratamento ou a prevenção da dor
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
NO169286C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater
CA2437409A1 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
RU2005108667A (ru) Производные n-биарилметиламиноциклоалканкарбоксамида

Legal Events

Date Code Title Description
FB Suspension of granting procedure